First-in-Class Phosphonate Linker-Drug Platform (ByonBoost™)
Checkpoint inhibitors (CPIs) provide durable responses and are a key treatment for many types of cancer. However, many patients do not respond to immune therapy, resulting in a need for well-tolerated immunotherapy that complements currently approved CPIs and overcome resistance and toxicity. One of the main resistance mechanisms is MHC downregulation in 40–90% of tumors, which limits recognition by classical αβ T cells. Our ByonBoost™ phosphonate linker-drug platform is aiming to deliver a range of antibody drug conjugates (ADCs) with high compatibility for solid oncology and hematological malignancies. Our frontrunner agent shown to be a potent and efficacious ADC targeted to a clinically validated target with tumor-killing activity across multiple tumor types and a clean profile in initial safety in PK/PD studies.
Need for well-tolerated immunotherapy that complements currently approved checkpoint inhibitor therapies
Proprietary immunostimulatory ADC platform, ByonBoost, indirectly activates γδ T cells, which are not dependent on MHC expression: overcoming checkpoint inhibitor resistance and toxicity.
Immune checkpoint therapy can elicit durable clinical responses, but a significant propotion of patients do not respond to immune therapy
Downregulation of MHC has been described in 40-90% of human tumors which prevents recognition of tumor cells by classical αβ T cells
Opportunity: γδ T cells provide MHC-independent recognition of cancer cells
ByonBoost™: A First-in-Class Phosphonate ADC Platform for Targeted Delivery of Phosphonates to Tumor Cell
ByonBoost™ can be targeted to heme and solid TAAs, delivering a phosphonate payload that activates BTN2/3 receptors and triggers cytotoxic γδ T cell–mediated tumor killing
Byondis’ Phosphonate ADCs
Selectively Eliminate Cancer Cells through Indirect Activation of γδ T Cells
Antifolate Linker-Drug Platform
Working to overcome antibody drug conjugate (ADC) resistance as therapies move into earlier treatment lines and in combination, our antifolate platform provides a differentiated and validated MOA with a payload designed to overcome systemic side effects.
Masked Therapeutics (ByonGuard™)
Our innovative universal masking platform, ByonGuard™, is designed to improve the therapeutic index of antibody-based therapies with no bespoke peptides needed.
